Physician profile
Mirjam Bryan
NPI 1568864189
$2,650.76
in general payments reported to CMS, 2019-2025
10 companies · $724 in 2025
The $724 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $345 · 2022: $312 · 2023: $417 · 2024: $854 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,993.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $858.54 | 2022-2025 | Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $503.24 | 2021-2024 | Invega |
| Neurocrine Biosciences, INC. | $385.52 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $347.32 | 2025 | Cobenfy |
| Abbvie INC. | $131.98 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.35 | 2024 | Caplyta |
| Gilead Sciences, INC. | $119.60 | 2024 | Epclusa |
| Alkermes, INC. | $85.97 | 2022 | |
| Alexion Pharmaceuticals, INC. | $49.93 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $48.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mirjam Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.